Market Outlook:

The AMD Drugs Market size is poised to reach USD 1,831.1 Million by 2024, with a projected escalation to USD 1,949.4 Million by 2032, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period (2025-2032).

Market development depends on rising germ diseases worldwide plus new product launches which boost pharmaceutical research funding while public programs support affordable drug delivery solutions. The number of elderly people increases while the spread of diabetes, hypertension, cancer, and infectious diseases keeps growing. Regular advancements in drug delivery technologies along with improved home healthcare options resulting from government-backed healthcare growth create favorable conditions for hospital advances and expands diagnostic care facilities which increases patient access to medical treatment.

Market Dynamics:

Driver:

The increasing number of people with chronic diseases worldwide will greatly boost the pharmaceutical delivery market growth. The aging population creates more cases of both type 2 diabetes mellitus and high blood pressure. Based on WHO data chronic diseases will represent 73% of all deaths by 2025 and these conditions will make up 60% of the worldwide disease burden. WHO estimates that people aged 60 and above will form twice the current population throughout the coming decade. With increased risk of chronic health issues elderly people will need superior medical support systems to meet their rising healthcare needs. The global increase in chronic disease cases creates strong demand for innovative drug delivery systems that work better.

Restraint:

The use of injectable drug delivery creates a danger of receiving needlesticks. The higher number of needlestick injuries and contaminated needle infections creates a worldwide health threat that endangers both medical staff and people receiving care. European Pharmaceutical Manufacturer reports more than two million occupational needlestick injuries happen each year although strict safety standards exist. The WHO recorded needlestick accidents in 2022 infected 36.7% of medical workers with hepatitis B and 39% with hepatitis C plus 4.4% who acquired HIV/AIDS. Since injectable drugs harm both patients and staff members their usage likely experiences negative impact.

Opportunity:

The drug delivery industry for pharmaceutical products will expand faster because patients prefer taking medications at home and for themselves. Older patients who make up the majority of drug delivery users in home care settings drive this market trend according to recent patterns. Being in charge of their health maneuvers helps patients gain control while living better with improved well-being. The consistent use of single-use medication devices promotes better use of prescribed medicines to achieve improved patient results.

Key Players:

• Regeneron Pharmaceuticals Inc. (US)
• Bayer AG (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Apellis Pharmaceuticals (US)
• Coherus BioSciences (US)
• Astellas Pharma Inc. (Japan)
• Biogen (US)
• STADA Arzneimittel AG  (Germany)
• Formycon AG (Germany)
• Others

Recent Development:

• In March 2024 Johnson & Johnson bought Ambrx Biopharma to enhance their medical research interests. This deal will increase J&J's dedication to researching better prostate cancer treatments and enhance its inventory of advanced medical treatments. 

• In January 2024, AbbVie put million US dollars into building new biologics facilities at its production plant in Singapore.

Segment Insights:

By Type of AMD

Several important developments boost the market demand for wet AMD drugs. Many older adults above 60 now develop wet AMD because the worldwide aging population makes them highly prone to the illness. New testing methods help doctors find AMD sooner to begin treatment effectively and drive medicine needs. People who need eye care and doctors understand its importance better because of their growing knowledge. Pioneer technologies in biologics and anti-VEGF treatment options help both patients and health practitioners deliver better results. More people can access healthcare for their eyes and spend more on healthcare in developing countries pushing up the need for these drugs. Research projects in development and new methods to deliver treatments spark investor interest which keeps driving market progress.

By Molecule

Many elements contribute to growing demand for Ranibizumab drugs to treat age-related macular degeneration (AMD). The growing older population creates demand because AMD develops more often in elderly people. Better healthcare services now find AMD cases sooner which prompts doctors to start treatment quickly. Doctors prefer using Ranibizumab due to its successful treatment that prevents vision loss and hinders AMD development. The public and medical community is discovering more treatment choices which increases how often people use these treatments. New methods of delivering medicine to make treatment plans easier for patients help keep them on their treatment plans. More people get diabetes from unhealthy life choices and need treatment options that include Ranibizumab. Increasing use of Ranibizumab shows its important role in clinical treatment of neovascular AMD while helping older adults keep a better quality of life.

Regional Insights:

The North American market for age-related macular degeneration drugs develops due to medical advances plus technological progress alongside demographic patterns. AMD most often affects people above 60 years old which makes the aging population the main reason behind the increased demand for AMD drugs in North America. As people grow older and live longer lives including the baby boom generation the number of AMD patients keeps increasing. The spread of AMD knowledge among people and better understanding of early diagnosis now leads more individuals to get treatment. Enhanced detection and monitoring technology through optical coherence tomography helps doctors find and track AMD better which leads to more prescription rates. New medical treatments such as ranibizumab and aflibercept improve patient results and make patients more likely to follow treatment directions in AMD care. Healthcare spending increases and insurance coverage for medical treatments make it easier for patients to obtain necessary treatments. Both populations in North America continue to experience growing needs for AMD medications.

Segmentation:

By Type of AMD

• Wet AMD 

• Dry AMD

By Product

• Eylea & Eylea HD

• Lucentis

• Vabysmo

• Syfovre

• Others

By Molecule

• Ranibizumab
• Aflibercept
• Faricimab

By Approval Type

• Biologic

• Biosimilar

By Region

North America

• USA

• Canada

• Mexico

Europe

• France

• UK

• Spain

• Germany

• Italy

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• South Korea

• Rest of Asia Pacific

Middle East & Africa

• GCC

• South Africa

• Rest of the Middle East & Africa

South America

• Brazil

• Argentina

• Rest of South America

What to Expect from Industry Profile?

1. Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the AMD Drugs Market in the world.

2. Use the PORTER’s Five Forces analysis to determine the competitive intensity and therefore market attractiveness of the Global AMD Drugs Market.

3. Leading company profiles reveal details of key AMD Drugs Market players’ global operations, strategies, financial performance & recent developments.

4. Add weight to presentations and pitches by understanding the future growth prospects of the Global AMD Drugs Market with forecast for the decade by both market share (%) & revenue (USD Million).

FAQ’s

1) What are the major factors driving the growth of the Global AMD Drugs Market?

• Rising geriatric population has intensified the demand for AMD Drugs.

2) What would be the CAGR of the Global AMD Drugs Market over the forecast period?

• The Global AMD Drugs Market is poised to grow at a CAGR of 11.3% from 2024 to 2032.

3) Which region will provide more business opportunities for the growth of the Global AMD Drugs Market in the future?

• The North America region is expected to create more opportunities in the market.

4) Who are the major players dominating the Global AMD Drugs Market?

• Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals (US), Coherus BioSciences (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG  (Germany), Formycon AG (Germany), and Others.

5) What are the segments in the Global AMD Drugs Market?

• By Type of AMD, By Product, By Molecule, By Approval Type are the industry key segments considered for research study.

6) What is the estimated market revenue for the Global AMD Drugs Market in 2032?

• The estimated revenue for the Global AMD Drugs Market in 2032 is USD 1,949.4 Million.